Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more
Tyra Biosciences Inc (TYRA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.080x
Based on the latest financial reports, Tyra Biosciences Inc (TYRA) has a cash flow conversion efficiency ratio of -0.080x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.38 Million) by net assets ($280.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tyra Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tyra Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tyra Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tyra Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangyin Jianghua Microelectronics Materials Co Ltd
SHG:603078
|
0.031x |
|
Hengkang Medical Group Co Ltd
SHE:002219
|
0.005x |
|
Foshan Saturday Shoes Co Ltd
SHE:002291
|
-0.028x |
|
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros
MC:LDA
|
0.278x |
|
Inv La Constru
SN:ILC
|
0.106x |
|
Castle Biosciences Inc
NASDAQ:CSTL
|
0.048x |
|
Taiflex Scientific Co Ltd
TW:8039
|
0.090x |
|
USINAS SID.MIN.GER. PFD A
F:U1S1
|
N/A |
Annual Cash Flow Conversion Efficiency for Tyra Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tyra Biosciences Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $343.15 Million | $-69.77 Million | -0.203x | +17.16% |
| 2023-12-31 | $204.26 Million | $-50.14 Million | -0.245x | -25.86% |
| 2022-12-31 | $257.83 Million | $-50.28 Million | -0.195x | -147.84% |
| 2021-12-31 | $301.74 Million | $-23.75 Million | -0.079x | -113.82% |
| 2020-12-31 | $-13.64 Million | $-7.76 Million | 0.569x | +3.08% |
| 2019-12-31 | $-4.74 Million | $-2.62 Million | 0.552x | -- |